# | Title | Journal | Year | Citations |
---|
1 | Angiogenesis, neurogenesis and brain recovery of function following injury | Current Opinion in Investigational Drugs | 2010 | 182 |
2 | Artemisinins for schistosomiasis and beyond | Current Opinion in Investigational Drugs | 2007 | 145 |
3 | Autophagy inhibition in combination cancer treatment | Current Opinion in Investigational Drugs | 2009 | 127 |
4 | Injury and repair mechanisms in ischemic stroke: considerations for the development of novel neurotherapeutics | Current Opinion in Investigational Drugs | 2009 | 120 |
5 | The modulatory role of melatonin on immune responsiveness | Current Opinion in Investigational Drugs | 2006 | 110 |
6 | Candida biofilms: antifungal resistance and emerging therapeutic options | Current Opinion in Investigational Drugs | 2004 | 103 |
7 | Insulin resistance and neurodegeneration: roles of obesity, type 2 diabetes mellitus and non-alcoholic steatohepatitis | Current Opinion in Investigational Drugs | 2009 | 99 |
8 | Angiotensin II as a pro-inflammatory mediator | Current Opinion in Investigational Drugs | 2002 | 99 |
9 | RAGE in inflammation: a new therapeutic target? | Current Opinion in Investigational Drugs | 2006 | 94 |
10 | Hyperthermia as an immunotherapy strategy for cancer | Current Opinion in Investigational Drugs | 2009 | 92 |
11 | Multimodal analgesia: its role in preventing postoperative pain | Current Opinion in Investigational Drugs | 2008 | 92 |
12 | Sirtuins: novel targets for metabolic disease | Current Opinion in Investigational Drugs | 2008 | 92 |
13 | FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels | Current Opinion in Investigational Drugs | 2010 | 92 |
14 | The endocannabinoid system: a drug discovery perspective | Current Opinion in Investigational Drugs | 2005 | 91 |
15 | Neurobiological mechanisms of addiction: focus on corticotropin-releasing factor | Current Opinion in Investigational Drugs | 2010 | 90 |
16 | Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic | Current Opinion in Investigational Drugs | 2002 | 90 |
17 | Mitotane for adrenocortical carcinoma treatment | Current Opinion in Investigational Drugs | 2005 | 90 |
18 | Neuroimmune interactions and pain: focus on glial-modulating targets | Current Opinion in Investigational Drugs | 2008 | 85 |
19 | Regenerative medicine through mesenchymal stem cells for bone and cartilage repair | Current Opinion in Investigational Drugs | 2002 | 79 |
20 | Bacteriophage therapy for the treatment of infections | Current Opinion in Investigational Drugs | 2009 | 79 |
21 | Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases | Current Opinion in Investigational Drugs | 2010 | 75 |
22 | The importance of 5-HT1A receptor agonism in antipsychotic drug action: rationale and perspectives | Current Opinion in Investigational Drugs | 2010 | 73 |
23 | New strategies for the treatment of infections associated with prosthetic joints | Current Opinion in Investigational Drugs | 2005 | 72 |
24 | STA-9090, a small-molecule Hsp90 inhibitor for the potential treatment of cancer | Current Opinion in Investigational Drugs | 2010 | 72 |
25 | Therapeutic impact of methoxyamine: blocking repair of abasic sites in the base excision repair pathway | Current Opinion in Investigational Drugs | 2004 | 70 |
26 | The pleuromutilin antibiotics: a new class for human use | Current Opinion in Investigational Drugs | 2010 | 69 |
27 | Pharmacokinetics of phosphorothioate antisense oligodeoxynucleotides | Current Opinion in Investigational Drugs | 2001 | 68 |
28 | COX-2 inhibitors as antidepressants and antipsychotics: clinical evidence | Current Opinion in Investigational Drugs | 2010 | 67 |
29 | Evidence for IL-1 receptor blockade as a therapeutic strategy for the treatment of depression | Current Opinion in Investigational Drugs | 2009 | 66 |
30 | PPARbeta/delta ligands as modulators of the inflammatory response | Current Opinion in Investigational Drugs | 2008 | 66 |
31 | Ramucirumab, a fully human mAb to the transmembrane signaling tyrosine kinase VEGFR-2 for the potential treatment of cancer | Current Opinion in Investigational Drugs | 2009 | 66 |
32 | Fatty acid biosynthesis as a target for novel antibacterials | Current Opinion in Investigational Drugs | 2004 | 65 |
33 | Corticotropin-releasing hormone modulators and depression | Current Opinion in Investigational Drugs | 2003 | 65 |
34 | Phosphodiesterase 10A inhibitors: a novel approach to the treatment of the symptoms of schizophrenia | Current Opinion in Investigational Drugs | 2007 | 65 |
35 | Pazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy | Current Opinion in Investigational Drugs | 2008 | 65 |
36 | Autoimmunity in autism | Current Opinion in Investigational Drugs | 2009 | 64 |
37 | Experimental therapeutics: targeting the redox Achilles heel of cancer | Current Opinion in Investigational Drugs | 2007 | 64 |
38 | BIBW-2992, a dual receptor tyrosine kinase inhibitor for the treatment of solid tumors | Current Opinion in Investigational Drugs | 2008 | 64 |
39 | FGF21: a novel prospect for the treatment of metabolic diseases | Current Opinion in Investigational Drugs | 2009 | 64 |
40 | The impact of carbapenemases on antimicrobial development and therapy | Current Opinion in Investigational Drugs | 2002 | 63 |
41 | Mitogen-activated protein kinases as potential targets for pain killers | Current Opinion in Investigational Drugs | 2004 | 63 |
42 | The road to licensure of a DNA vaccine | Current Opinion in Investigational Drugs | 2007 | 63 |
43 | The development of nanobodies for therapeutic applications | Current Opinion in Investigational Drugs | 2009 | 63 |
44 | Drug interactions with HMG-CoA reductase inhibitors (statins): the importance of CYP enzymes, transporters and pharmacogenetics | Current Opinion in Investigational Drugs | 2010 | 63 |
45 | CD200 and its receptors as targets for immunoregulation | Current Opinion in Investigational Drugs | 2005 | 62 |
46 | MicroRNAs: small but potent oncogenes or tumor suppressors | Current Opinion in Investigational Drugs | 2006 | 62 |
47 | Diamidines as antitrypanosomal, antileishmanial and antimalarial agents | Current Opinion in Investigational Drugs | 2006 | 61 |
48 | Diamidines for human African trypanosomiasis | Current Opinion in Investigational Drugs | 2010 | 61 |
49 | ABC transporters and inhibitors: new targets, new agents | Current Opinion in Investigational Drugs | 2002 | 60 |
50 | Therapeutic potential of neuronal two-pore domain potassium-channel modulators | Current Opinion in Investigational Drugs | 2007 | 60 |